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ABSTRACTS
Gregory L. Moneta, MD, Abstracts Section EditorMalignancies, prothrombotic mutations, and the risk of venous
thrombosis
Blom JW, Doggen CJM, Osanto S, et al. JAMA 2005;293:715-22.
Conclusion:There is an increased risk of venous thrombosis in patients
with cancer. The risk is greatest in the first few months after diagnosis and in
the presence of distal metastasis. Patients also with Factor V Leiden and
prothrombin 20210A mutations have even higher risk.
Summary: This is a report of the Multiple Environmental and Genetic
Assessment (MEGA) of Risk Factors for Venous Thrombosis Study. MEGA
is a case controlled population based study evaluating risk of venous throm-
bosis with various risk factors. This report details risk of venous thrombosis
with cancer and the joint effects of cancer and selected genetic mutations
predisposing to venous thrombosis. Patients were identified at 6 anticoagu-
lation clinics in the Netherlands betweenMarch 1, 1999, andMay 31, 2002.
Patients included were those 18-70 years of age with a first time diagnosis of
pulmonary embolism or lower extremity deep venous thrombosis. Control
patients, (partners of the patients with venous thrombosis) were also utilized
in the study. Both patients and controls received a questionnaire to evaluate
acquired risk factors for venous thrombosis. Once anticoagulation therapy
had been discontinued for three months, patients and controls were inter-
viewed and blood taken for analysis of Factor V Leiden and prothrombin
20210A mutations.
In patients with malignancy, the overall risk of venous thrombosis was
increased 7 times (odds ratio [OR], 6.7; 95% CI, 5.2-8.6). The highest risk
was present in patients with hematologic malignancies (OR 28.0, 95% CI,
4.0-199.7). Risk was also substantially increased in patient with gastrointes-
tinal cancers (OR 18.9; 95% CI, 4.6-77.8), and patients with pulmonary
malignancies (OR 24.8; 95% CI, 3.4-181.1). Risk was highest in the first
several months following malignancy diagnosis (adjusted OR 53.5; 95% CI,
8.6-334.3). In patients with cancer the presence of distal metastatic disease
further increased the risk of venous thromboembolism (VTE) compared to
patients without metastatic disease (adjusted OR, 19.8; 95% CI, 2.6-149.1).
The combination of cancer and Factor V Leiden mutation increased the risk
of VTE 12 times compared to patients with Factor V Leiden mutation and
no diagnosed malignancy. Results were similar for patients with and without
cancer with respect to the prothrombin 20210A mutation.
Comment: The data raises the question as to whether patients with
cancer should be screened for Factor V Leiden and prothrombin 20210A
mutation and treated with prophylactic anticoagulation therapy if a muta-
tion is present. Also the question arises whether prophylactic anticoagulation
is indicated in patients with malignancies associated with an especially high
risk for VTE. The cost effectiveness of such strategies and the ultimate ability
of such strategies to prolong life or improve quality of life is clear in patients
with cancer who are undergoing surgery or active chemotherapy (ACTA
Haematol 2001;106:73-80). There is currently no data to suggest routine
prophylaxis for VTE in all cancer patients would be effective. However, the
results of the current study suggest certain subgroups of patients with cancer
should be studied more closely for potential benefit of routine VTE prophy-
laxis.
Complications of the Cox-II inhibitors parecoxib and valdecoxib after
cardiac surgery
Nussmeier NA, Whelton AA, Brown MT, et al. N Engl J Med 2005;352:
1081-91.
Conclusion: Patients treated with coronary artery bypass grafting and
who have Parecoxib and Valdecoxib utilized for postoperative pain control
had an increased incidence of postoperative cardiovascular events.
Summary: There is serious concern that, in nonsurgical settings, use of
Cox-II inhibitors increases risk of thromboembolic events long-term. The
authors sought to evaluate the safety of Parecoxib and Valdecoxib after
coronary artery bypass grafting. This was a randomized, double-blind study.
After coronary artery bypass grafting, patients were treated for ten days and
followed for thirty days. The Cox-II inhibitors used in this study were
Valdecoxib (Bextra, Pfizer) and its intravenous prodrug Parecoxib (Dymas-
tat, Pfizer). After coronary artery bypass grafting, patients were randomly
assigned to receive intravenous Parecoxib for at least three days followed by
oral Valdecoxib through day ten or were assigned to be treated with
intravenous placebo followed by oral Valdecoxib, or placebo, for ten days.
There were 1,671 patients enrolled in the study and all patients also had
access to opiate based medications. The primary endpoint was the frequency
of pre-defined adverse events (cardiovascular events, renal failure or dysfunc-
tion, gastroduodenal ulceration, and wound-healing complications).
1242Compared to the group given placebo alone, the groups given Pare-
coxib and Valdecoxib, placebo andValdecoxib, and placebo andValdecoxib,
all had higher rates of confirmed adverse events (4.0% in the placebo group
versus 7.4% in each of the coxib groups; risk ratio for each comparison, 1.9;
95% CI, 1.1-3.2; P .02). Cardiovascular events including myocardial
infarction, cardiac arrest, stroke, and pulmonary embolism were particular
more frequent among patients given Parecoxib and Valdecoxib (2.0% versus
0.5%; risk ratio 3.7; 95% CI, 1.0-13.5; P .03).
Comment: Previous data on the adverse effects of Cox-II inhibitors has
focused on long- term thromboembolic risk. There has been data to suggest
Cox-II inhibitors could exert significant opiate sparing effects after surgical
procedures. The current study, however, suggests patients with coronary
artery disease who undergo CABG may be adversely impacted by the use of
Cox-II inhibitors to control perioperative pain. While no such data currently
exists to implicate Cox-II inhibitors and increased cardiovascular complica-
tions after peripheral vascular surgery, the current data may imply Cox-II
inhibitors should be avoided in patients undergoing peripheral vascular
surgery as well.
Intensive lipid lowering with atorvastatin in patients with stable coro-
nary disease
LaRosa JC, Grundy SM, Waters DD, and the Treating to New Targets
(TNT) Investigators. N Engl J Med 2005;352:1425-35.
Conclusion: In patients with stable coronary heart disease, intensive
lipid-lowering therapy with 80mg Atorvastatin daily provides additional
clinical benefit beyond that with treatment of 10mg of Atorvastatin per day.
Summary: Recent trials indicate intensive lipid-lowering therapy be-
yond traditionally recommended levels in patients with acute coronary
syndromes provides increased benefit with respect to cardiovascular end-
points compared to traditional lipid-lowering therapy in such patients
(N Engl J Med 2004;50:1495-504, and J Am Col Cardiology 2004;
44:1772-9). This study investigated the safety and efficacy of lowering LDL
cholesterol below 100 mg/dL in patients with stable coronary disease.
Eligible patients were men and women 35-75 years of age who had clinically
evident coronary heart disease. Screening of 18,469 patients took place at
256 sites in 14 countries, with 83.7% of these patients felt to be eligible to
enter the open-label run in period of the study. Of these, 5,461 patients were
excluded after the open label run in phase. Most exclusions were secondary
to failure to meet randomization criteria. There were 10,001 patients
ultimately randomized to receive double-blind treatment with either 10 mg
or 80 mg daily of Atorvastatin. Primary endpoint was occurrence of a first
major cardiovascular event (death from coronary heart disease, nonfatal
non-procedure related myocardial infarction, fatal or nonfatal stroke, or
resuscitation after cardiac arrest). Randomization took place between July
1998 and December 1999.
During treatment mean LDL cholesterol levels were 77 mg/dL with
80 mg Atorvastatin daily and 101 mg/dL with 10 mg Atorvastatin daily.
Persistent elevations in liver aminotransferase occurred in 1.2% of the 80 mg
Atorvastatin daily group versus 0.2% in the 10 mg Atorvastatin daily group
(P  0.001). Eight point seven percent (n  434) of the patients receiving
80 mg of Atorvastatin had a primary endpoint. Ten point nine percent (n
548) of the patients receiving 10mg of Atorvastatin had a primary endpoint.
The absolute reduction in rate of major cardiovascular events was 2.2% with
a 22% relative reduction (hazard ratio, 0.78; 95% CI, 0.69-0.89; P .001).
Overall, mortality did not differ between the two groups. Discontinuation of
treatment based on adverse events occurred in 7.2% of the 80 mg Atorva-
statin group versus 5.3% in the 10mg Atorvastatin group (P .001). There
were five cases rhabdomyolysis (2 in the 80 mg Atorvastatin group and 3 in
the 10 mg Atorvastatin group).
Comment: The safety data for the two doses of Atorvastatin utilized in
this trial are consistent with other large scale trials of this drug (NEngl JMed
2004; 350:1495-504 and Lancet 2003; 361:1149-58). The trial was not
adequately powered to detect differences in risk of death from any cause.
Nevertheless, the study is part of a growing body of evidence suggesting that
lowering LDL cholesterol levels significantly below traditionally recom-
mended values has clinical benefit.
Clinical predictors of transient ischemic attack, stroke, or death within
thirty days of carotid angioplasty and stenting
Kastrup A, Groschel K, Schulz JB, et al. Stroke 2005;36:787-91.Conclusion: Patients with increased age, recent stroke, or hemispheric
transient ischemic attack (TIA), have higher risk of peri-procedure compli-
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(ICA) stenosis than younger patients or those with asymptomatic ICA
stenosis or retinal TIA.
Summary: It appears combined stroke and death rates after CAS are
higher in symptomatic than asymptomatic patients (Stroke 2003; 34:813-819).
The authors sought to identify specific clinical risk factors thatmay influence post
procedural complications after CAS. This was a retrospective review of a pro-
spectively maintained database involving 299 patients (217 men, 82 women,
mean age 69  9 years), who underwent CAS for either asymptomatic (n 
129, 43%) or symptomatic (n  170, 57%) ICA stenosis. Logistic regression
analysis was used to determine risk factors associated with peri-procedure
(30-day) complications (any TIA, minor stroke, major stroke or death).
Overall, the 30-day TIA rate was 3.7%. Theminor stroke rate was 5.3%,
and the major stroke rate 0.7%, with a death rate of 0.7%. Patients presenting
with a minor stroke or hemispheric TIA had a higher risk of complication
than asymptomatic patients (odds ratio [OR] 5.69; 95% confidence interval
[CI], 2.03-19.57; P .001). Complication rate in patients presenting with
a retinal TIA and in asymptomatic patients were similar (OR, 1.42; 95% CI,
0.13-9.02; p  0.6). Advanced age (OR 1.06; 95% CI 1-1.11; P  .05),
stroke (OR, 8.0; 95% CI, 2.26-24.1; P .01), or hemispheric TIA (OR 4.7;
95% CI, 1.16-13.3; P .004), were all independent predictors of combined
30-day occurrence of any TIA, stroke, or death.
Comment: Identification of potential risk factors for CAS is crucial to
proper patient selection for CAS and for patient counseling. This study helps
identify presenting clinical features that may be important in selecting the
patients for CAS. Unfortunately, angiographic features of the carotid steno-
ses were not reported. It is likely that a combination of angiographic and
clinical features will ultimately prove most useful in the selection of patients
for CAS.
Post carotid endarterectomy hyperperfusion or reperfusion syndrome?
Karapanayiotides T, Meuli R, Devuyst G, et al. Stroke 2005; 36:21-26
Conclusion: So called hyperperfusion syndrome after carotid endar-
terectomy may, in some cases, be more correctly described as resulting from
reperfusion rather than hyperperfusion.
Summary:Hyperperfusion syndrome (HS) following carotid revascu-
larization is thought to occur in a previously chronically hypoperfused
cerebral hemisphere with impaired cerebrovascular autoregulation. The
authors of this study sought to study hemispheric perfusion in patients
following carotid endarterectomy who had symptoms consistent with so-
called HS. Patients were selected from 388 consecutive patients who under-
went carotid endarterectomy. Five of these patients presented 2-7 days after
carotid endarterectomy with partial seizures and focal neurologic deficits.
Three had a cerebral hemorrhage. These patients were considered to have
HS. All had undergone carotid endarterectomy for very high-grade carotid
stenosis. Patients were assessed for relative inter-hemispheric differences of
cerebral blood flow by perfusion weighted MRI imaging and with diffusion
weighted (DWI) MRI imaging. In addition, middle cerebral blood flow
velocity measurements were obtained with transcranial Doppler.
There were no hyper-intensity pathologic DWI abnormalities in any of
the five patients. This is consistent with an absence of acute ischemic or
cytotoxic hemispheric edema. Perfusion weighted imaging documented a
20-44% relative inter-hemispheric difference in cerebral blood flow in favor
of the hemisphere ipsilateral to the recent carotid endarterectomy. Transcra-
nial Doppler middle cerebral artery flow velocities were not abnormally
increased in any patient.
Comment: The classic definition of HS following carotid endarterec-
tomy is a 100% increase in cerebral blood flow compared to preoperative
values (J Neurosurg 2003; 99:504-510). The current study suggests symp-
toms and pathology consistent with what is regarded asHS following carotid
endarterectomy can occur in the presence of relatively mild increased cere-
bral perfusion. The hemodynamic abnormalities leading to the clinical
manifestations of HS may be milder and more complicated than previously
appreciated.
Risk factors for venous thrombosis in swedish children and adolescents
Rask O, Berntorp E, Ljung R. ACTA Paediatrica 2005:94:717-22
Conclusion: There are prothrombotic risk factors present in almost all
children and adolescents with venous thrombosis.
Summary: Venous thrombosis has an incidence of approximately
10/10,000 in adults and 0.07/10,000 children. (Haematologica 1999;84:
59-70 and Journal Pediatr Hematol Oncol 1997;19:7-22). Little informa-
tion, however, exists regarding prothrombotic risk factors in children with
venous thromboembolism (VTE). The authors attempted to identify pro-
thrombotic risk factors in adolescents and children following their first VTE
event. There were 128 consecutive adolescents and children (newborn to 20
years) who were evaluated following referral to a regional coagulation center
in southern Sweden. The prothrombotic risk factors evaluated included
protein C, protein S, antithrombin; resistant to activated protein C; geno-
types FV – G1691A, II-G20210A, MTHFR-C677T, MTHFR-A1298C,
and coagulation factors VIII and XI. There was also a retrospective collec-
tion of clinical data.Identifiable genetic factors related to VTE were present in 53 of 83
(64%) subjects who had follow up blood sampling. Of these 17/83 (20%)
had two or more inherited risk factors. There was a combination of acquired
risk factors and genetic risk factors in 45/83 subjects (54%). At least 1 risk
factor was present in 77/83 subjects (93%). There was a peak frequency of
VTE in children less than 1 year of age with a second peak occurring during
adolescents. Levels of coagulation factors VIII and XI were age appropriate
and showed a normal Gaussian distribution.
Comment:While venous thromboembolism is unusual in children and
adolescents, the data here suggest that a VTE event in a child should be
investigated with a detailed hypercoagulable panel. The yield is high enough
to merit routine use in children with VTE.
Changes in false lumen after transluminal stent-graft placement in
aortic dissections six years experience
Kusagawa H, Shimono T, Ishieda M et al. Circulation 2005;111:2951-7
Conclusion: Treatment of aortic dissection with stent graft placement
results in obliteration of the false lumen more often in the acute setting than
in chronic dissections.
Summary: The authors chose to review their aortic stent graft patients
where stent grafts were placed for treatment of aortic dissection. The goal was to
quantify long term results in changes in the false lumen over time. There were
49 patients who had primary tears in the descending aorta who were treated
with aortic stent graft placement. Followup ranged from4months to 6 years. In
thirty-two cases the patients were treated in the acute setting and there were 17
chronic dissections treated. In the acute cases there were 15 retrograde dissec-
tions (Stanford type A) treated. Patients were followed with serial CT scans.
In patients with Stanford type A retrograde dissections treated with
stent grafts the false lumen in the ascending aorta was obliterated within
three months in 93% of the cases. Serial CT scans of 17 acute dissections and
11 chronic dissections showed the average false lumen diameter of the
proximal mid and distal descending aorta in the acute dissection group was
15.9, 16.2, and 15.6mm respectively. In the chronic dissection group the
average false lumen diameters of the proximal mid and distal descending
aorta were 28.1, 25.2, and 21.0mm respectively. After 2 years the false
lumen in the thoracic aorta was completely obliterated in 76% of the acute
dissections and 36% of the chronic dissections treated with stent grafts.
There were no cases of late rupture.
Comment: The study suggests a move towards more interventional
treatment of acute thoracic dissection. Certainly, the success of obliterating
the retrograde dissection into the aortic arch from a descending primary tear
suggests that acute treatment of Type B dissections will be considered and
performed in additional locations. Medical management of Type B dissec-
tion is highly effective but the fact that the chronic dissections have more
difficulty in late obliteration of the false lumen after treatment with stent
grafts suggests that it may be prudent to eventually treat Type B dissections
acutely with stent graft placement.
Aortic neck attachment failure and the aneurx graft: incidence, treat-
ment options, and early results
Azizzadeh A, Sanchez LA, Rubin BG, et al. Annals Vascular Surgery
2005;19:516-21
Conclusion: Proximal attachment failure associated with the AneuRx
endoluminal aortic stent graft is relatively uncommon and associated with
unfavorable neck anatomy.
Summary: The frequency of proximal attachment failure associated with
the AneuRx aortic stent graft is unclear. The authors evaluated the need for
intervention in patients with suboptimal proximal fixation of an AneuRx stent
graft. They assessed the feasibility and early success of a variety of treatment
strategies. There were 365 endovascular aneurysm repairs performed using the
AneuRxgraft fromOctober 1999 toOctober 2003.Mean followupwas 23.7
14.8 months. There were 20 patients considered for treatment following stent
grafting. Fourteen had a Type 1 endoleak, one had a Type 3 endoleak, and five
had an inadequate proximal seal zone (less than 1cm). Of these patients, 18
(90%) were treated successfully. (Nine with AneuRx cuffs, six with Talent cuffs,
five with aortic stents, one with a redo aortic endograft, and two with surgical
conversion.) Of the 20 patients with suboptimal initial outcome, one refused
treatment and suffered late aneurysm rupture and one had persistent Type 1
endoleak despite endovascular treatment. Following the secondary interven-
tion, there were no further endoleaks or graft migrations detected at a mean
followup of 13.9 11.8 months.
Comment: Followup periods in this study are relatively short, with a
mean followup of 23.7  14.8 months following initial placement of the
AneuRx stent graft and a mean followup of only 13.9  11.8 months
following secondary intervention in 20 patients with suboptimal proximal
fixation. Likely there will be more proximal attachment site failures as time
goes by. The follow-up periods presented here are simply too short to
suggest either continued use of or immediate abandonment of the AneuRx
graft system. Longer term data is required. A comparison of rates of proximal
site attachment rate failure with other types of aortic stent grafts is also
required.
